NCT03059719View on ClinicalTrials.gov

Clinical Trial for PB-119 in Subjects With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 8, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

October 27, 2016

Conditions
Type II Diabetes Mellitus
Interventions
BIOLOGICAL

Exenatide injection(Byetta)

BIOLOGICAL

PB-119 injection

Trial Locations (1)

100191

No.1 Hospital of Peking University, Beijing

All Listed Sponsors
lead

PegBio Co., Ltd.

OTHER

NCT03059719 - Clinical Trial for PB-119 in Subjects With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter